Surfaxin: Epitomizing Esteve

The progress of Esteve's lead compound Surfaxin illustrates how the Spanish group is building a robust, yet risk-controlled pipeline to supplement its co-marketing activities. The compound may also become the first marketed drug in which Esteve played an active development role, and bears testament to the private group's partnering appeal.